Aprepitant (EMEND) is the first commercially available drug from a new class of agents, the Substance P/neurokinin NK-1 receptor antagonists. Aprepitant is indicated for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with highly emetogenic chemotherapy in adults. Its ability to antagonize the effects of Substance P has lead to greater understanding of the pathophysiology of nausea and vomiting. Its broad range of activity against a wide variety of central and peripheral emetogenic stimuli make it potentially useful in non-chemotherapy related nausea and vomiting.
Prommer, E. (2005). Aprepitant (EMEND): the role of substance P in nausea and vomiting. Journal of Pain & Palliative Care Pharmacotherapy, 19(3), 31–9. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/16219609